ASND•Ascendis Pharma plans to launch YUVIWEL in Germany in Q1 2027, subject to European Commission authorization. A final decision is expected in Q4 2026; maintaining orphan designation could provide 10 years of EU market exclusivity if adopted.
Ascendis Pharma plans its first EU launch of TransCon CNP as YUVIWEL in Germany in Q1 2027, subject to European Commission authorization. The treatment is for achondroplasia in children aged two and older with open epiphyses, and a final authorization decision is expected in Q4 2026.
The EMA's orphan medicines committee recommended maintaining orphan designation. If the European Commission adopts the recommendation, it could provide 10 years of EU market exclusivity.
